MedKoo Biosciences, Inc.
Tel:   +1-919-636-5577    Fax:   +1-919-980-4831    Email:   sales@medkoo.com
Search
Login Register
Search
MedKoo Cat#: 407492 | Name: SU1498
Featured New

Description:

WARNING: This product is for research use only, not for human or veterinary use.

SU1498 is a selective inhibitor of the receptor tyrosine kinase VEGF receptor 2 (VEGFR2, aka FLK1; IC50 = 700 nM).

Chemical Structure

SU1498
SU1498
CAS# 168835-82-3

Theoretical Analysis

MedKoo Cat#: 407492

Name: SU1498

CAS#: 168835-82-3

Chemical Formula: C25H30N2O2

Exact Mass: 390.2307

Molecular Weight: 390.53

Elemental Analysis: C, 76.89; H, 7.74; N, 7.17; O, 8.19

Price and Availability

Size Price Availability Quantity
100mg USD 750.00 2 Weeks
200mg USD 1,250.00 2 Weeks
500mg USD 2,450.00 2 Weeks
1g USD 3,850.00 2 Weeks
2g USD 6,450.00 2 Weeks
Bulk Inquiry
Buy Now
Add to Cart
Related CAS #
No Data
Synonym
SU-1498; SU 1498; SU1498; AG-1498; AG 1498; AG1498; Tyrphostin SU 1498
IUPAC/Chemical Name
(2E)-2-cyano-3-[4-hydroxy-3,5-bis(1-methylethyl)phenyl]-N-(3-phenylpropyl)-2-propenamide
InChi Key
JANPYFTYAGTSIN-FYJGNVAPSA-N
InChi Code
InChI=1S/C25H30N2O2/c1-17(2)22-14-20(15-23(18(3)4)24(22)28)13-21(16-26)25(29)27-12-8-11-19-9-6-5-7-10-19/h5-7,9-10,13-15,17-18,28H,8,11-12H2,1-4H3,(H,27,29)/b21-13+
SMILES Code
O=C(NCCCC1=CC=CC=C1)/C(C#N)=C/C2=CC(C(C)C)=C(O)C(C(C)C)=C2
Appearance
Solid powder
Purity
>98% (or refer to the Certificate of Analysis)
Shipping Condition
Shipped under ambient temperature as non-hazardous chemical. This product is stable enough for a few weeks during ordinary shipping and time spent in Customs.
Storage Condition
Dry, dark and at 0 - 4 C for short term (days to weeks) or -20 C for long term (months to years).
Solubility
Soluble in DMSO
Shelf Life
>2 years if stored properly
Drug Formulation
This drug may be formulated in DMSO
Stock Solution Storage
0 - 4 C for short term (days to weeks), or -20 C for long term (months).
HS Tariff Code
2934.99.9001
More Info
Product Data
Product Data
Instruction
View handling instruction
Biological target:
SU1498 is an inhibitor of Flk-1 with an IC50 value of 700 nM. SU1498 is a very weak inhibitor of PDGFR-kinase, EGFR-kinase and HER-2 kinase with IC50 values > 50 μM.
In vitro activity:
SU1498 stimulated accumulation of phosphorylated ERKs in HUVECs and in human aortic endothelial cells, dependent on the functioning of the upstream components of the MAPK pathway, B-Raf, and MEK kinases. The enhanced accumulation of phospho-ERKs was observed only in cells that were stimulated with sphingosine 1-phosphate or protein growth factors; SU1498 alone was ineffective. SU1498 acted by blocking the kinase activity of phospho-ERK. Reference: J Biol Chem. 2004 Feb 13;279(7):5716-24. https://pubmed.ncbi.nlm.nih.gov/14625306/
In vivo activity:
SU1498 is a promising therapy for ocular neovascularization. SU1498 did not show any cytotoxicity and tissue toxicity. Administration of SU1498 reduced the size and thickness of choroidal neovascularization and decreased the mean length and mean number of corneal neovascular vessels induced by alkali burn. SU1498 pretreatment significantly reduced the proliferation, migration, and tube formation ability of HUVECs. SU1498 played the anti-angiogenic role through the regulation of p38-MAPK signaling. Reference: Biomed Pharmacother. 2020 Aug;128:110248. https://pubmed.ncbi.nlm.nih.gov/32454287/
Solvent mg/mL mM
Solubility
DMSO 10.0 25.61
Note: There can be variations in solubility for the same chemical from different vendors or different batches from the same vendor. The following factors can affect the solubility of the same chemical: solvent used for crystallization, residual solvent content, polymorphism, salt versus free form, degree of hydration, solvent temperature. Please use the solubility data as a reference only. Warming and sonication will facilitate dissolving. Still have questions? Please contact our Technical Support scientists.

Preparing Stock Solutions

The following data is based on the product molecular weight 390.53 Batch specific molecular weights may vary from batch to batch due to the degree of hydration, which will affect the solvent volumes required to prepare stock solutions.

Recalculate based on batch purity %
Concentration / Solvent Volume / Mass 1 mg 5 mg 10 mg
1 mM 1.15 mL 5.76 mL 11.51 mL
5 mM 0.23 mL 1.15 mL 2.3 mL
10 mM 0.12 mL 0.58 mL 1.15 mL
50 mM 0.02 mL 0.12 mL 0.23 mL
Formulation protocol:
1. Kisielewska J, Ligeza J, Klein A. The effect of tyrosine kinase inhibitors, tyrphostins: AG1024 and SU1498, on autocrine growth of prostate cancer cells (DU145). Folia Histochem Cytobiol. 2008;46(2):185-91. doi: 10.2478/v10042-008-0028-1. PMID: 18519236. 2. Boguslawski G, McGlynn PW, Harvey KA, Kovala AT. SU1498, an inhibitor of vascular endothelial growth factor receptor 2, causes accumulation of phosphorylated ERK kinases and inhibits their activity in vivo and in vitro. J Biol Chem. 2004 Feb 13;279(7):5716-24. doi: 10.1074/jbc.M308625200. Epub 2003 Nov 18. PMID: 14625306. 3. Shu-Ya T, Qiu-Yang Z, Jing-Jing L, Jin Y, Biao Y. Suppression of pathological ocular neovascularization by a small molecule, SU1498. Biomed Pharmacother. 2020 Aug;128:110248. doi: 10.1016/j.biopha.2020.110248. Epub 2020 May 23. PMID: 32454287. 4. Cebulla CM, Jockovich ME, Boutrid H, Piña Y, Ruggeri M, Jiao S, Bhattacharya SK, Feuer WJ, Murray TG. Lack of effect of SU1498, an inhibitor of vascular endothelial growth factor receptor-2, in a transgenic murine model of retinoblastoma. Open Ophthalmol J. 2008 Apr 2;2:62-7. doi: 10.2174/1874364100802010062. PMID: 19517030; PMCID: PMC2694596.
In vitro protocol:
1. Kisielewska J, Ligeza J, Klein A. The effect of tyrosine kinase inhibitors, tyrphostins: AG1024 and SU1498, on autocrine growth of prostate cancer cells (DU145). Folia Histochem Cytobiol. 2008;46(2):185-91. doi: 10.2478/v10042-008-0028-1. PMID: 18519236. 2. Boguslawski G, McGlynn PW, Harvey KA, Kovala AT. SU1498, an inhibitor of vascular endothelial growth factor receptor 2, causes accumulation of phosphorylated ERK kinases and inhibits their activity in vivo and in vitro. J Biol Chem. 2004 Feb 13;279(7):5716-24. doi: 10.1074/jbc.M308625200. Epub 2003 Nov 18. PMID: 14625306.
In vivo protocol:
1. Shu-Ya T, Qiu-Yang Z, Jing-Jing L, Jin Y, Biao Y. Suppression of pathological ocular neovascularization by a small molecule, SU1498. Biomed Pharmacother. 2020 Aug;128:110248. doi: 10.1016/j.biopha.2020.110248. Epub 2020 May 23. PMID: 32454287. 2. Cebulla CM, Jockovich ME, Boutrid H, Piña Y, Ruggeri M, Jiao S, Bhattacharya SK, Feuer WJ, Murray TG. Lack of effect of SU1498, an inhibitor of vascular endothelial growth factor receptor-2, in a transgenic murine model of retinoblastoma. Open Ophthalmol J. 2008 Apr 2;2:62-7. doi: 10.2174/1874364100802010062. PMID: 19517030; PMCID: PMC2694596.
1: Gawlak G, Son S, Tian Y, O'Donnell JJ 3rd, Birukov KG, Birukova AA. Chronic high-magnitude cyclic stretch stimulates EC inflammatory response via VEGF receptor 2-dependent mechanism. Am J Physiol Lung Cell Mol Physiol. 2016 Jun 1;310(11):L1062-70. doi: 10.1152/ajplung.00317.2015. Epub 2016 Mar 18. PubMed PMID: 26993523; PubMed Central PMCID: PMC4935472. 2: Cai H, Xue Y, Li Z, Hu Y, Wang Z, Liu W, Li Z, Liu Y. Roundabout4 suppresses glioma-induced endothelial cell proliferation, migration and tube formation in vitro by inhibiting VEGR2-mediated PI3K/AKT and FAK signaling pathways. Cell Physiol Biochem. 2015;35(5):1689-705. doi: 10.1159/000373982. Epub 2015 Mar 18. PubMed PMID: 25833462. 3: Pan WK, Li P, Guo ZT, Huang Q, Gao Y. Propranolol induces regression of hemangioma cells via the down-regulation of the PI3K/Akt/eNOS/VEGF pathway. Pediatr Blood Cancer. 2015 Aug;62(8):1414-20. doi: 10.1002/pbc.25453. Epub 2015 Mar 1. PubMed PMID: 25728347. 4: Mesti T, Savarin P, Triba MN, Le Moyec L, Ocvirk J, Banissi C, Carpentier AF. Metabolic impact of anti-angiogenic agents on U87 glioma cells. PLoS One. 2014 Jun 12;9(6):e99198. doi: 10.1371/journal.pone.0099198. eCollection 2014. PubMed PMID: 24922514; PubMed Central PMCID: PMC4055646. 5: Kang Z, Zhu H, Luan H, Han F, Jiang W. Curculigoside A induces angiogenesis through VCAM-1/Egr-3/CREB/VEGF signaling pathway. Neuroscience. 2014 May 16;267:232-40. doi: 10.1016/j.neuroscience.2014.02.050. Epub 2014 Mar 12. Erratum in: Neuroscience. 2014 Sep 5;275:1. PubMed PMID: 24631678. 6: Kang Z, Zhu H, Jiang W, Zhang S. Protocatechuic acid induces angiogenesis through PI3K-Akt-eNOS-VEGF signalling pathway. Basic Clin Pharmacol Toxicol. 2013 Oct;113(4):221-7. doi: 10.1111/bcpt.12094. Epub 2013 Jul 6. PubMed PMID: 23738793. 7: Kang Z, Jiang W, Luan H, Zhao F, Zhang S. Cornin induces angiogenesis through PI3K-Akt-eNOS-VEGF signaling pathway. Food Chem Toxicol. 2013 Aug;58:340-6. doi: 10.1016/j.fct.2013.05.017. Epub 2013 May 20. PubMed PMID: 23702325. 8: Kim EK, Kang SW, Kim JY, Min K, Kim TI. Modulation of bevacizumab-induced toxicity for cultured human corneal fibroblasts. Invest Ophthalmol Vis Sci. 2013 Jun 6;54(6):3922-31. doi: 10.1167/iovs.12-11287. PubMed PMID: 23640039. 9: Pan Z, Fukuoka S, Karagianni N, Guaiquil VH, Rosenblatt MI. Vascular endothelial growth factor promotes anatomical and functional recovery of injured peripheral nerves in the avascular cornea. FASEB J. 2013 Jul;27(7):2756-67. doi: 10.1096/fj.12-225185. Epub 2013 Apr 8. PubMed PMID: 23568776; PubMed Central PMCID: PMC3688738. 10: Klettner A, Westhues D, Lassen J, Bartsch S, Roider J. Regulation of constitutive vascular endothelial growth factor secretion in retinal pigment epithelium/choroid organ cultures: p38, nuclear factor κB, and the vascular endothelial growth factor receptor-2/phosphatidylinositol 3 kinase pathway. Mol Vis. 2013;19:281-91. Epub 2013 Jan 3. PubMed PMID: 23401656; PubMed Central PMCID: PMC3566904. 11: Laird M, Woad KJ, Hunter MG, Mann GE, Robinson RS. Fibroblast growth factor 2 induces the precocious development of endothelial cell networks in bovine luteinising follicular cells. Reprod Fertil Dev. 2013;25(2):372-86. doi: 10.1071/RD12182. PubMed PMID: 23153420. 12: Hills CE, Younis MY, Bennett J, Siamantouras E, Liu KK, Squires PE. Calcium-sensing receptor activation increases cell-cell adhesion and β-cell function. Cell Physiol Biochem. 2012;30(3):575-86. doi: 10.1159/000341439. Epub 2012 Jul 25. PubMed PMID: 22832156. 13: Francescone R, Scully S, Bentley B, Yan W, Taylor SL, Oh D, Moral L, Shao R. Glioblastoma-derived tumor cells induce vasculogenic mimicry through Flk-1 protein activation. J Biol Chem. 2012 Jul 13;287(29):24821-31. doi: 10.1074/jbc.M111.334540. Epub 2012 May 31. PubMed PMID: 22654102; PubMed Central PMCID: PMC3397909. 14: Kiuchi T, Lee H, Mikami T. Regular exercise cures depression-like behavior via VEGF-Flk-1 signaling in chronically stressed mice. Neuroscience. 2012 Apr 5;207:208-17. doi: 10.1016/j.neuroscience.2012.01.023. Epub 2012 Jan 20. PubMed PMID: 22306286. 15: Woad KJ, Hunter MG, Mann GE, Laird M, Hammond AJ, Robinson RS. Fibroblast growth factor 2 is a key determinant of vascular sprouting during bovine luteal angiogenesis. Reproduction. 2012 Jan 1;143(1):35-43. doi: 10.1530/REP-11-0277. Epub 2011 Oct 13. PubMed PMID: 21998077. 16: Hung HS, Chu MY, Lin CH, Wu CC, Hsu SH. Mediation of the migration of endothelial cells and fibroblasts on polyurethane nanocomposites by the activation of integrin-focal adhesion kinase signaling. J Biomed Mater Res A. 2012 Jan;100(1):26-37. doi: 10.1002/jbm.a.33224. Epub 2011 Oct 4. PubMed PMID: 21972215. 17: Ligęza J, Ligęza J, Klein A. Growth factor/growth factor receptor loops in autocrine growth regulation of human prostate cancer DU145 cells. Acta Biochim Pol. 2011;58(3):391-6. Epub 2011 Aug 29. PubMed PMID: 21887406. 18: Ferla R, Bonomi M, Otvos L Jr, Surmacz E. Glioblastoma-derived leptin induces tube formation and growth of endothelial cells: comparison with VEGF effects. BMC Cancer. 2011 Jul 19;11:303. doi: 10.1186/1471-2407-11-303. PubMed PMID: 21771332; PubMed Central PMCID: PMC3146945. 19: Buharalioglu CK, Song CY, Yaghini FA, Ghafoor HU, Motiwala M, Adris T, Estes AM, Malik KU. Angiotensin II-induced process of angiogenesis is mediated by spleen tyrosine kinase via VEGF receptor-1 phosphorylation. Am J Physiol Heart Circ Physiol. 2011 Sep;301(3):H1043-55. doi: 10.1152/ajpheart.01018.2010. Epub 2011 Jun 3. PubMed PMID: 21642504; PubMed Central PMCID: PMC3191073. 20: Lu KT, Sun CL, Wo PY, Yen HH, Tang TH, Ng MC, Huang ML, Yang YL. Hippocampal neurogenesis after traumatic brain injury is mediated by vascular endothelial growth factor receptor-2 and the Raf/MEK/ERK cascade. J Neurotrauma. 2011 Mar;28(3):441-50. doi: 10.1089/neu.2010.1473. Epub 2011 Jan 9. PubMed PMID: 21091268.

View History

Disufen

Disufen